香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 - 1 - 石四藥集團有限公司(「本公司」，連同其附屬公司，「本集團」)董事局(「董事局」)欣然公告， 本集團已取得中國國家藥品監督管理局有關新增2ml 規格的複合磷酸氫鉀注射液的藥品生產註 冊批件，屬於化學藥品第3類，視同通過一致性評價。 複合磷酸氫鉀注射液是複方製劑，主要當口服或腸內營養無法進行、不足或有禁忌時，用於糾 正成人和兒童患者的低磷血症及用於成人和兒童患者的腸外營養。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二六年一月二十六日 自願公告 產品開發的最新進展 ...

Core Insights - The article highlights the net inflow and outflow of funds in the Hong Kong stock market, with Xiaomi Group, Tencent Holdings, and China Construction Bank leading in net inflows, while the Yingfu Fund, Hang Seng China Enterprises, and Southern Hang Seng Technology experienced the highest net outflows [1] Group 1: Net Inflows - Xiaomi Group-W (01810) recorded a net inflow of 1.07 billion, representing a 16.36% increase in its closing price [2] - Tencent Holdings (00700) saw a net inflow of 863 million, with a 7.49% increase in its closing price [2] - China Construction Bank (00939) had a net inflow of 699 million, with a significant 41.06% increase in its closing price [2] Group 2: Net Outflows - Yingfu Fund (02800) experienced the largest net outflow of 6.289 billion, reflecting a -31.44% change in its closing price [2] - Hang Seng China Enterprises (02828) had a net outflow of 2.880 billion, with a -17.89% change in its closing price [2] - Southern Hang Seng Technology (03033) faced a net outflow of 1.289 billion, showing a -11.37% change in its closing price [2] Group 3: Net Inflow Ratios - 361 Degrees (01361) led with a net inflow ratio of 74.40%, with a net inflow of 8.9117 million [3] - BRILLIANCE CHI (01114) followed with a net inflow ratio of 64.04%, amounting to a net inflow of 36.4910 million [3] - Qin Port Co. (03369) had a net inflow ratio of 61.05%, with a net inflow of 846,600 [3] Group 4: Net Outflow Ratios - Wisdom Hong Kong 100 (02825) had a net outflow ratio of -100.00%, with a net outflow of -18,200 [3] - Stone Pharmaceutical Group (02005) recorded a net outflow ratio of -68.86%, with a net outflow of -14.1501 million [3] - Dexion Shipping (02510) experienced a net outflow ratio of -53.53%, with a net outflow of -10.0204 million [3]

智通财经APP获悉，石四药集团(02005)、方正控股(00418)、天福(06868)、永升服务(01995)、VITASOY INT'L(00345)、天润云(02167)、绿城服务(02869)、亲亲食品(01583)、信利国际(00732)、天安卓健 (00383)、舜宇光学科技(02382)、吉利汽车(00175)、同方友友(01868)、心玮医疗-B(06609)、捷利交易宝 (08017)、威高股份(01066)、津上机床中国(01651)、碧桂园服务(06098)、宝胜国际(03813)、腾讯控股 (00700)、易点云(02416)、天伦燃气(01600)、名创优品(09896)、枫叶教育(01317)、小米集团- W(01810)、美丽田园医疗健康(02373)、绿茶集团(06831)、HYPEBEAST(00150)、美亨实业(01897)、多 点数智(02586)、巨子生物(02367)、思派健康(00314)、九毛九(09922)、KEEP(03650)、手回集团 (02621)、连连数字(02598)、汇通达网络(09878)、迈富时(02556)、叮当健康(09886)、家乡互动 ...

Summary of Key Points Core Viewpoint - The latest shareholder equity disclosures for several companies, including Zhongjia Guoxin, Boan Biotech, Fudan Zhangjiang, and others, were made on January 12, 2026, indicating significant changes in shareholdings among various institutional investors [1]. Group 1: Zhongjia Guoxin (00899) - Jiang Xiaojun increased holdings from 5.60 million shares to 16.80 million shares, representing a holding percentage of 3.77% [2] - Li Jiayi raised holdings from 23.39 million shares to 70.18 million shares, with a holding percentage of 15.76% [2] - Lin Bilin increased holdings from 0.10 million shares to 31.30 million shares, now holding 7.03% [2] - FULL TENDA DEVELOPMENT increased holdings from 23.88 million shares to 71.65 million shares, holding 16.09% [2] - GREEN DEER HOLDINGS LIMITED increased holdings from 0.10 million shares to 31.30 million shares, now holding 7.03% [2] - Yao Jigen increased holdings from 24.96 million shares to 74.88 million shares, with a holding percentage of 16.82% [2] Group 2: Boan Biotech (06955) - Yantai Green Leaf Pharmaceutical Holdings reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] - Luye Geneora Holding Limited acquired 50 million shares, holding 8.03% [2] - AsiaPharm Investments reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] - Shandong Green Leaf Pharmaceutical reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] - Luye Pharma Hong Kong Limited reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] Group 3: Other Companies - Fudan Zhangjiang (01349): Yang Zongmeng reduced holdings from 59.33 million shares to 55.79 million shares, now holding 7.85% [2] - Prosperity Industrial Trust (00778): ESR Asset Management increased holdings from 76.05 million shares to 80.57 million shares, now holding 3.92% [2] - Shishi Pharmaceutical Group (02005): Qu Jiguang maintained holdings at 1.233 billion shares, holding 41.79% [2] - Zheli Holdings (02209): Lei Baicheng slightly reduced holdings from 31.31 million shares to 31.05 million shares, now holding 7.43% [2]

智通财经APP讯，石四药集团(02005)发布公告，于2026年1月9日，该公司斥资138.87万港元回购45.6万 股。 ...

石四药集团(02005)发布公告，于2026年1月9日，该公司斥资138.87万港元回购45.6万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 表格類別： 股票 狀態： 新提交 公司名稱： 石四藥集團有限公司 呈交日期： 2026年1月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | ...

Core Viewpoint - The company, Stone Four Pharmaceutical Group, has been actively repurchasing its shares, indicating a potential confidence in its stock value and future performance [2] Summary by Category Share Buyback Activity - On January 8, the company repurchased 1.486 million shares at a price range of HKD 3.030 to HKD 3.050, totaling HKD 4.5217 million [2] - The stock closed at HKD 3.050 on the same day, reflecting a 0.99% increase, with a total trading volume of HKD 20.5504 million [2] - Since January 5, the company has conducted share buybacks for four consecutive days, accumulating a total of 5.214 million shares repurchased, with a total expenditure of HKD 15.585 million [2] - During this period, the stock price has increased by 6.64% [2] Buyback Details - The detailed buyback information is as follows: - January 8: 1.486 million shares at a maximum price of HKD 3.050 and a minimum price of HKD 3.030, totaling HKD 4.5217 million [2] - January 7: 1.128 million shares at a maximum price of HKD 3.030 and a minimum price of HKD 3.010, totaling HKD 3.4063 million [2] - January 6: 1.500 million shares at a maximum price of HKD 3.000 and a minimum price of HKD 2.960, totaling HKD 4.4694 million [2] - January 5: 1.100 million shares at a maximum price of HKD 2.920 and a minimum price of HKD 2.890, totaling HKD 3.1876 million [2]

Core Viewpoint - The company, 石四药集团, announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will repurchase 1.486 million shares at a total cost of HKD 4.5217 million [1] - The buyback price per share ranges from HKD 3.03 to HKD 3.05 [1]

格隆汇1月8日丨石四药集团(02005.HK)发布公告，2026年1月8日耗资452.17万港元回购148.6万股，回购 价格每股3.03-3.05港元。 ...